Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase

EMBO Molecular Medicine

Volumn 6, Issue 12, 2014, Pages 1525-1541

  Peter, Stefanie ^a   Bultinck, Jennyfer ^b   Myant, Kevin ^c   Jaenicke, Laura A ^a   Walz, Susanne ^a   Müller, Judith ^d   Gmachl, Michael ^e   Treu, Matthias ^e   Boehmelt, Guido ^e   Ade, Carsten P ^a   Schmitz, Werner ^a   Wiegering, Armin ^f   Otto, Christoph ^f   Popov, Nikita ^a,g   Sansom, Owen ^c   Kraut, Norbert ^e   Eilers, Martin ^a,g  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GHENT UNIVERSITY   (Belgium)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Colorectal cancer; HUWE1; MIZ1; MYC; Ubiquitination

Indexed keywords

LIGASE INHIBITOR; MYC PROTEIN; SHORT HAIRPIN RNA; UBIQUITIN LIGASE HUWE1; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; HUWE1 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MOLECULAR LIBRARY; ONCOPROTEIN; PROTEIN BINDING; ZBTB17 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL GROWTH; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME INHIBITION; GENE REPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TRANSACTIVATION; TRANSCRIPTION INITIATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR LIBRARY; PATHOPHYSIOLOGY; PHARMACOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, SCID; ONCOGENE PROTEIN P55(V-MYC); PROTEIN BINDING; SMALL MOLECULE LIBRARIES; TRANSCRIPTIONAL ACTIVATION; UBIQUITIN-PROTEIN LIGASES;

EID: 84918519265     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201403927     Document Type: Article

References (51)

1. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, et al (2005) The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123: 409-421
2. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et al (2013) Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24: 75-89
3. CancerGenomeAtlasNetwork (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337
4. Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, et al (2013) CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med 5: 1067-1086
5. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121: 1071-1083
6. Dai MS, Sears R, Lu H (2007) Feedback regulation of c-Myc by ribosomal protein L11. Cell Cycle 6: 2735-2741
7. Dang CV (2012) MYC on the path to cancer. Cell 149: 22-35
8. D'Arca D, Zhao X, Xu W, Ramirez-Martinez NC, Iavarone A, Lasorella A (2010) Huwe1 ubiquitin ligase is essential to synchronize neuronal and glial differentiation in the developing cerebellum. Proc Natl Acad Sci USA 107: 5875-5880
9. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917
10. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22: 2755-2766
11. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207
12. Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20: 2423-2435
13. Herkert B, Dwertmann A, Herold S, Abed M, Naud JF, Finkernagel F, Harms GS, Orian A, Wanzel M, Eilers M (2010) The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis. J Cell Biol 188: 905-918
14. Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, Bernards R, Eilers M (2008) Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J 27: 2851-2861
15. Honnemann J, Sanz-Moreno A, Wolf E, Eilers M, Elsasser HP (2012) Miz1 is a critical repressor of cdkn1a during skin tumorigenesis. PLoS ONE 7: e34885
16. Inoue S, Hao Z, Elia AJ, Cescon D, Zhou L, Silvester J, Snow B, Harris IS, Sasaki M, Li WY, et al (2013) Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev 27: 1101-1114
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90
18. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP (2003) Skp2 regulates Myc protein stability and activity. Mol Cell 11: 1177-1188
19. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, et al (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44: 325-340
20. Laherty CD, Yang W-M, Sun J-M, Davie JR, Seto E, Eisenman RN (1997) Histone deacetylases associated with the mSin3 corepressor mediate Mad transcritional repression. Cell 89: 349-356
21. Langmead B (2010) Aligning short sequencing reads with Bowtie. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al] Chapter 11: Unit 11 17
22. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydbring P, Weidung I, Nakayama K, Nakayama KI, et al (2003) The F-Box Protein Skp2 Participates in c-Myc Proteosomal Degradation and Acts as a Cofactor for c-Myc-Regulated Transcription. Mol Cell 11: 1189-1200
23. Li Z, Boone D, Hann SR (2008) Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci USA 105: 18794-18799
24. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143
25. Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, et al (2011) The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci USA 108: 3665-3670
26. Micel LN, Tentler JJ, Smith PG, Eckhardt GS (2013) Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 31: 1231-1238
27. Oskarsson T, Essers MA, Dubois N, Offner S, Dubey C, Roger C, Metzger D, Chambon P, Hummler E, Beard P, et al (2006) Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 20: 2024-2029
28. Pandya RK, Partridge JR, Love KR, Schwartz TU, Ploegh HL (2010) A structural element within the HUWE1 HECT domain modulates self-ubiquitination and substrate ubiquitination activities. J Biol Chem 285: 5664-5673
29. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M (1997) An alternative pathway for gene regulation by Myc. EMBO J 16: 5672-5686
30. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR (2004) p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717
31. Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26: 841-842
32. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139-140
33. Salghetti SE, Kim SY, Tansey WP (1999) Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 18: 717-726
34. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-679
35. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262-265
36. Smith KN, Singh AM, Dalton S (2010) Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell 7: 343-354
37. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683
38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550
39. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, et al (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511: 483-487
40. Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG, Eilers M (2008) A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat Cell Biol 10: 1051-1061
41. Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN, Clurman BE (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085-9090
42. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250
43. Wiese KE, Walz S, vonEyss B, Wolf E, Athineos D, Sansom O, Eilers M (2013) The Role of MIZ-1 in MYC-Dependent Tumorigenesis. Cold Spring Harb Perspect Med 3, 91-100.
44. Yang Y, Do H, Tian X, Zhang C, Liu X, Dada LA, Sznajder JI, Liu J (2010) E3 ubiquitin ligase Mule ubiquitinates Miz1 and is required for TNFalpha-induced JNK activation. Proc Natl Acad Sci USA 107: 13444-13449
45. Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22: 6151-6159
46. Zhang J, Kan S, Huang B, Hao Z, Mak TW, Zhong Q (2011) Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev 25: 2610-2618
47. Zhang Q, Spears E, Boone DN, Li Z, Gregory MA, Hann SR (2013) Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proc Natl Acad Sci USA 110: 978-983
48. Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, Iavarone A, Lasorella A (2008) The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol 10: 643-653
49. Zhao X, D DA, Lim WK, Brahmachary M, Carro MS, Ludwig T, Cardo CC, Guillemot F, Aldape K, Califano A, et al (2009) The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev Cell 17: 210-221.
50. Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121: 1085-1095
51. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463